stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) Operating cash flow
Tango Therapeutics, Inc.'s operating cash flow for fiscal 2025 was −$138.9M, compared with −$131.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$143.9M. Over the past ten years it has ranged from −$138.9M (fiscal 2025) to $70.1M (fiscal 2020) — the current reading is the lowest in ten years. Operating cash flow has fallen for 5 consecutive fiscal years. Tango Therapeutics, Inc. ranks 498th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$138.9M | — |
| FY2024 | −$131.5M | — |
| FY2023 | −$118.0M | — |
| FY2022 | −$109.1M | — |
| FY2021 | −$59.5M | — |
| FY2020 | $70.1M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$38.9M | — |
| Mar 2026 | −$44.4M | — |
| Dec 2025 | −$29.7M | — |
| Sep 2025 | −$31.0M | — |
| 20 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $97.5M |
| ABCL AbCellera Biologics Inc. compare | −$94.9M |
| PBLS Parabilis Medicines, Inc. compare | −$118.1M |
| TNGX Tango Therapeutics, Inc. | −$143.9M |
| EWTX Edgewise Therapeutics, Inc. compare | −$158.4M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$190.0M |
| IRON Disc Medicine, Inc. compare | −$197.5M |
| RLAY Relay Therapeutics, Inc. compare | −$212.2M |
| XENE Xenon Pharmaceuticals Inc. compare | −$337.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement